Key statistics
As of last trade, Autolus Therapeutics PLC (AUTL:NSQ) traded at 1.70, 53.85% above the 52 week low of 1.11 set on Apr 11, 2025.
52-week range
| Open | 1.66 |
|---|---|
| High | 1.72 |
| Low | 1.63 |
| Bid | 1.70 |
| Offer | 1.71 |
| Previous close | 1.71 |
| Average volume | 2.15m |
|---|---|
| Shares outstanding | 266.14m |
| Free float | 8.82m |
| P/E (TTM) | -- |
| Market cap | 455.11m USD |
| EPS (TTM) | -0.8447 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 16:01 GMT.
More ▼
- Autolus Therapeutics to Participate in Upcoming Investor Conferences
- Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026
- Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform
- Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
- Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
- Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
- NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
- Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
- Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
More ▼
